Evidence for positive selection driving the evolution of HIV-1 env under potent antiviral therapy

被引:41
作者
Frost, SDW
Günthard, HF
Wong, JK
Havlir, D
Richman, DD
Brown, AJL
机构
[1] Univ Calif San Diego, Treatment Ctr, Sch Med, Dept Pathol, San Diego, CA 92103 USA
[2] Univ Edinburgh, Inst Cell Anim & Populat Biol, Ctr HIV Res, Edinburgh EH8 9YL, Midlothian, Scotland
[3] Univ Zurich Hosp, Dept Internal Med, Div Infect Dis, Zurich, Switzerland
[4] San Diego Vet Affairs Hlth Sci Ctr, San Diego, CA USA
关键词
HIV-1; env; evolution; positive selection; antiviral therapy;
D O I
10.1006/viro.2000.0887
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In HIV-infected individuals treated with potent antiretroviral therapy, viable virus can be isolated from latently infected cells several years into therapy, due to the long life of these cells, ongoing replication replenishing this population, or both. We have analysed the Vs region of the HIV-1 env gene isolated from six patients who have undergone 2 years of potent antiretroviral therapy without frank failure of viral suppression. We show that in two (and possibly three) patients, the sequence changes between baseline virus and virus isolated from infected cells persisting 2 years into infection result from positive selection driving adaptive evolution, occurring either prior to or during therapy. Our analyses suggest low-level replication despite absence of drug resistance due to drug sanctuary sites, or to low-level ongoing replication in the presence of alterations in the selective environment during therapy, perhaps due to a decline in HIV-specific immune responsiveness or changes in target cell pools. In one patient, genetic divergence between baseline plasma and infected cells isolated during therapy may reflect the long half-life of some of these persistent cell populations and the divergence of viral subpopulations that occurred prior to therapy. (C) 2001 Academic Press.
引用
收藏
页码:250 / 258
页数:9
相关论文
共 26 条
[1]   CAUSES OF HIV DIVERSITY [J].
BONHOEFFER, S ;
HOLMES, EC ;
NOWAK, MA .
NATURE, 1995, 376 (6536) :125-125
[2]   Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy [J].
Chun, TW ;
Stuyver, L ;
Mizell, SB ;
Ehler, LA ;
Mican, JAM ;
Baseler, M ;
Lloyd, AL ;
Nowak, MA ;
Fauci, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (24) :13193-13197
[3]   DEVELOPMENT OF A QUASI-SPECIES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INVIVO [J].
CICHUTEK, K ;
MERGET, H ;
NORLEY, S ;
LINDE, R ;
KREUZ, W ;
GAHR, M ;
KURTH, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (16) :7365-7369
[4]   Parallel evolution of drug resistance in HIV: Failure of nonsynonymous/synonymous substitution rate ratio to detect selection [J].
Crandall, KA ;
Kelsey, CR ;
Imamichi, H ;
Lane, HC ;
Salzman, NP .
MOLECULAR BIOLOGY AND EVOLUTION, 1999, 16 (03) :372-382
[5]   Rapid, transient changes at the env LOCUS of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance [J].
Delwart, EL ;
Pan, H ;
Neumann, A ;
Markowitz, M .
JOURNAL OF VIROLOGY, 1998, 72 (03) :2416-2421
[6]   Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [J].
Finzi, D ;
Blankson, J ;
Siliciano, JD ;
Margolick, JB ;
Chadwick, K ;
Pierson, T ;
Smith, K ;
Lisziewicz, J ;
Lori, F ;
Flexner, C ;
Quinn, TC ;
Chaisson, RE ;
Rosenberg, E ;
Walker, B ;
Gange, S ;
Gallant, J ;
Siliciano, RF .
NATURE MEDICINE, 1999, 5 (05) :512-517
[7]   Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [J].
Finzi, D ;
Hermankova, M ;
Pierson, T ;
Carruth, LM ;
Buck, C ;
Chaisson, RE ;
Quinn, TC ;
Chadwick, K ;
Margolick, J ;
Brookmeyer, R ;
Gallant, J ;
Markowitz, M ;
Ho, DD ;
Richman, DD ;
Siliciano, RF .
SCIENCE, 1997, 278 (5341) :1295-1300
[8]  
GOLDMAN N, 1994, MOL BIOL EVOL, V11, P725
[9]   Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection - 100-week follow-up [J].
Gulick, RM ;
Mellors, JW ;
Havlir, D ;
Eron, JJ ;
Gonzalez, C ;
McMahon, D ;
Jonas, L ;
Meibohm, A ;
Holder, D ;
Schleif, WA ;
Condra, JH ;
Emini, EA ;
Isaacs, R ;
Chodakewitz, JA ;
Richman, DD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :35-41
[10]  
Günthard HF, 1999, J VIROL, V73, P9404